The Renin Angiotensin Aldosterone System in Obesity and Hypertension Roles in the Cardiorenal Metabolic Syndrome

被引:121
作者
Cabandugama, Peminda K. [1 ]
Gardner, Michael J. [1 ]
Sowers, James R. [1 ,2 ,3 ]
机构
[1] Univ Missouri, Dept Med, Diabet & Cardiovasc Ctr, Div Endocrinol, D109 Diabet Ctr UHC,One Hosp Dr, Columbia, MO 65212 USA
[2] Univ Missouri, Dept Physiol & Pharmacol, One Hosp Dr, Columbia, MO 65212 USA
[3] Harry S Truman VA Hosp, 800 Hosp Dr, Columbia, MO 65201 USA
基金
美国国家卫生研究院;
关键词
Obesity; Insulin resistance; Angiotensin II; Adipocyte; Hypertension; ADIPOSE-TISSUE; SYMPATHETIC ACTIVATION; INSULIN-RESISTANCE; DIABETES-MELLITUS; LEPTIN; INHIBITION; DIET; DEFICIENCY; SOCIETY;
D O I
10.1016/j.mcna.2016.08.009
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In the United States, more than 50 million people have blood pressure at or above 120/80 mm Hg. All components of cardiorenal metabolic syndrome (CRS) are linked to metabolic abnormalities and obesity. A major driver for CRS is obesity. Current estimates show that many of those with hypertension and CRS show some degree of systemic and cardiovascular insulin resistance. Several pathophysiologic factors participate in the link between hypertension and CRS. This article updates recent literature with a focus on the function of insulin resistance, obesity, and renin angiotensin aldosterone system-mediated oxidative stress on endothelial dysfunction and the pathogenesis of hypertension.
引用
收藏
页码:129 / +
页数:11
相关论文
共 43 条
[11]   The adipose-tissue renin-angiotensin-aldosterone system:: role in the metabolic syndrome? [J].
Engeli, S ;
Schling, P ;
Gorzelniak, K ;
Boschmann, M ;
Janke, E ;
Ailhaud, G ;
Teboul, M ;
Massiéra, F ;
Sharma, AA .
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 2003, 35 (06) :807-825
[12]   Review of direct renin inhibition by aliskiren [J].
Friedrich, Stefanie ;
Schmieder, Roland E. .
JOURNAL OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM, 2013, 14 (03) :193-196
[13]  
FROHLICH ED, 1983, HYPERTENSION, V5, P71
[14]   The impart of ACE inhibitors or angiotensin II type 1 receptor blockers on the development of new-onset type 2 diabetes [J].
Gillespie, EL ;
White, CM ;
Kardas, M ;
Lindberg, M ;
Coleman, CI .
DIABETES CARE, 2005, 28 (09) :2261-2266
[15]   SYMPATHETIC ACTIVATION IN OBESE NORMOTENSIVE SUBJECTS [J].
GRASSI, G ;
SERAVALLE, G ;
CATTANEO, BM ;
BOLLA, GB ;
LANFRANCHI, A ;
COLOMBO, M ;
GIANNATTASIO, C ;
BRUNANI, A ;
CAVAGNINI, F ;
MANCIA, G .
HYPERTENSION, 1995, 25 (04) :560-563
[16]   Renin-angiotensin-sympathetic crosstalks in hypertension: reappraising the relevance of peripheral interactions [J].
Grassi, G .
JOURNAL OF HYPERTENSION, 2001, 19 (10) :1713-1716
[17]   Receptor-mediated regional sympathetic nerve activation by leptin [J].
Haynes, WG ;
Morgan, DA ;
Walsh, SA ;
Mark, AL ;
Sivitz, WI .
JOURNAL OF CLINICAL INVESTIGATION, 1997, 100 (02) :270-278
[18]   The Future Burden of CKD in the United States: A Simulation Model for the CDC CKD Initiative [J].
Hoerger, Thomas J. ;
Simpson, Sean A. ;
Yarnoff, Benjamin O. ;
Pavkov, Meda E. ;
Burrows, Nilka Rios ;
Saydah, Sharon H. ;
Williams, Desmond E. ;
Zhuo, Xiaohui .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2015, 65 (03) :403-411
[19]   Sympathetic neural activation in nondiabetic metabolic syndrome and its further augmentation by hypertension [J].
Huggett, RJ ;
Burns, J ;
Mackintosh, AF ;
Mary, DASG .
HYPERTENSION, 2004, 44 (06) :847-852
[20]  
James PA., 2014, JAMA-J AM MED ASSOC, V311, P507, DOI [10.1001/jama.2013.284427, DOI 10.1001/JAMA.2013.284427]